The Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis (START-FAP) trial will begin enrolling patients in the next several weeks at Massachusetts General Hospital (MGH) in Boston.
The Company also announced that it has successfully transferred all GMP-related stability testing to a contract services organization.
Marina chief medical officer Alan Dunton said that CEQ508 has the potential to be a safe and efficacious therapeutic for a patient population with no currently approved pharmaceutical alternative.
Marina R&D executive vice president Richard Ho said they are encouraged by the positive safety results from first cohort and advancement represents for CEQ508 and the tkRNAi platform overall.